

1

2

3

4 **A Novel Method to Visualize Active Small GTPases Unveils
5 Distinct Sites of Sar1 Activation During Collagen Secretion.**

6

7

8 Miharu Maeda¹, Masashi Arakawa¹, Yukie Komatsu¹, and Kota Saito¹

9

10 ¹ Department of Biological Informatics and Experimental Therapeutics, Graduate School
11 of Medicine, Akita University 1-1-1, Hondo, Akita, 010-8543, Japan

12

13 *e-mail: ksaito@med.akita-u.ac.jp

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

1 **Abstract**

2 Small GTPases are essential in various cellular signaling pathways, and detecting their
3 activation within living cells is crucial for understanding cellular processes. Fluorescence
4 resonance energy transfer is widely used to study the interaction between activated small
5 GTPases and their effectors, but it is limited to those with well-defined effectors,
6 excluding Sar1. Here, we present a novel method, SAIYAN (Small GTPase ActIvity
7 ANalyzing), for detecting the activation of endogenous small GTPases via fluorescent
8 signals utilizing a split mNeonGreen system. We demonstrated Sar1 activation at the
9 endoplasmic reticulum (ER) exit site and successfully detected its activation state in
10 various cellular conditions. Utilizing the SAIYAN system in collagen-secreting cells, we
11 discovered activated Sar1 localized both at ER exit sites and ER-Golgi intermediate
12 compartment (ERGIC) regions. Additionally, impaired collagen secretion led to the
13 confinement of activated Sar1 at the ER exit sites, underscoring the significance of Sar1
14 activation through the ERGIC in collagen secretion.

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

1 INTRODUCTION

2 Small GTPases, cycling between inactive guanosine diphosphate (GDP) and active
3 guanosine triphosphate (GTP) forms, serve as molecular switches in various cellular
4 processes, including cell proliferation, growth, differentiation, motility, and membrane
5 trafficking^{1,2,3}. The activation of these small GTPases is catalyzed by guanine nucleotide
6 exchange factors (GEFs), which destabilize the binding of GDP to GTPase, thereby
7 facilitating its transition to the free form capable of recruiting cytoplasmic GTP. Upon
8 binding to GTP, the protein interacts with effectors to execute cellular functions.
9 Generally, the intrinsic GTPase activity of small GTPases is relatively slow, and
10 inactivation is facilitated by GTPase-activating proteins (GAPs)⁴.

11 The conventional approach to assessing GTPase activity *in vitro* relies on the use of
12 radioisotopes^{5,6}. Methods such as differential tryptophan fluorescence measurements of
13 small G proteins in their GDP- and GTP-bound states can be used as potential
14 improvements to these assays for GTPases containing tryptophan residues (excluding the
15 Ras family)^{6,7}. Another approach involves the use of a fluorescent nucleotide such as
16 mant-GTP⁸.

17 In addition to the *in vitro* assays, the measurement of GTPase activity within cells is
18 essential, as it directly reflects the broad cellular responses mediated by GTPases with
19 effector proteins. There are currently three primary methods for measuring the activity of
20 small GTPases within cells. Initially, ³²Pi labeling of cells was used to directly measure
21 the ratio of bound nucleotides to small GTPases^{9,10}. Pulse-labeled cells were extracted,
22 followed by immunoprecipitation of small GTPases, and the bound nucleotides were
23 resolved using thin-layer chromatography to determine the proportion of GDP to GTP.
24 Although highly sensitive, this assay requires radioisotope labeling, is time-consuming,
25 and lacks the ability to monitor changes over time.

26 Alternatively, the pull-down assay offers a method for measuring activity^{11,12}. In this
27 method, cells are extracted, activated small GTPases are captured by effector proteins,
28 and the number of bound GTPases is quantified using western blotting. Despite being
29 relatively straightforward, this assay still requires cell extraction, and GTPase hydrolysis
30 needs to be taken into account during experiments.

31 The third assay utilizes fluorescence resonance energy transfer (FRET)-based
32 biosensors¹³ to transfect cells, enabling the timely measurement of GTPase activity within
33 living cells. The Raichu, Ras superfamily, and interacting protein chimeric unit represent

1 the first intramolecular biosensors designed to detect FRET between YFP and CFP upon
2 Ras activation and its interaction with the effector Raf¹⁴. Although this method has been
3 successfully employed for various GTPases, it is limited to GTPases with well-defined
4 effector molecules. Moreover, the overexpression of FRET sensors in cells restricts the
5 monitoring of endogenous protein activity to specific cellular locations.

6 Split fluorescent systems offer versatile tools for a wide array of applications,
7 including systematic endogenous tagging for visualizing endogenous protein localization
8 and detecting membrane contact sites^{15, 16, 17, 18}. In this study, we used this system to
9 measure the activation of endogenous small GTPases in living cells. Our approach allows
10 detection of Sar1 activation under various physiological locations and conditions.
11 Furthermore, this novel system has potential for application across a broad spectrum of
12 different GTPases, and its effectiveness is discussed in subsequent sections.

13

14

1 RESULTS

2 Validation of SAIYAN technology

3 Sar1 is a small GTPase with an amphipathic N-terminus, belonging to the Arf-family¹⁹.
4 Upon activation by the guanine nucleotide exchange factor (GEF) Sec12, the N-terminus
5 of Sar1 gets inserted into the endoplasmic reticulum (ER) membrane to facilitate the
6 recruitment of Sec23/Sec24^{20, 21, 22}. Sec23 acts both as an effector by interacting with
7 activated Sar1 and as a GTPase-activating protein (GAP) for Sar1²³. This dual role poses
8 challenges for the development of conventional FRET-based sensors to monitor Sar1
9 activity.

10 To detect Sar1 activation within living cells, we initially established stable cell lines
11 expressing 10 of the 11 bundles of mNeonGreen2 (mNG₁₋₁₀) tethered to the ER
12 membrane in HeLa cells, which were obtained by fusion with the membrane-spanning
13 region of TANGO1S and an HA tag (Fig. 1a). This cell line was named HA-mNG₁₋₁₀.
14 Following doxycycline induction, we verified that the constructs labeled with HA were
15 distributed throughout the ER, exhibiting a characteristic reticular staining pattern that
16 colocalized with PDI (Supplementary Fig. 1a, upper panel). However, this construct did
17 not produce any mNeonGreen2 (mNG) signal (Supplementary Fig. 1a, upper panel). Next,
18 we transiently expressed Sar1A constructs containing a FLAG tag, followed by a glycine
19 linker fused to the 11th bundle of mNG (Sar1A-FLAG-mNG₁₁) in HA-mNG₁₋₁₀ cells (Fig.
20 1a). No mNG signal was detected in the absence of HA-mNG₁₋₁₀ induction
21 (Supplementary Fig. 1b, upper panel). However, upon induction of HA-mNG₁₋₁₀, mNG
22 signals became apparent (Fig. 1b, upper panel; Supplementary Fig. 1a, bottom panel;
23 Supplementary Fig. 1b, bottom panel). These mNG signals exhibited a pattern distinct
24 from those of HA or PDI, appearing as punctate structures in the ER membrane network
25 (Supplementary Fig. 1a, bottom panel). Costaining with Sec16, a well-established ER exit
26 site marker, revealed mNG localization at these sites (Fig. 1b, upper panel)²⁴. Notably,
27 FLAG staining, representing the entire Sar1A protein irrespective of its nucleotide status,
28 was distributed in both the cytoplasm and ER exit sites, maintaining its localization
29 regardless of the expression of HA-mNG₁₋₁₀ (Supplementary Fig. 1b). This observation
30 indicated that Sar1A-FLAG-mNG₁₁ was not artificially recruited to the ER membrane by
31 mNG₁₋₁₀ to form complete mNG proteins. Therefore, we inferred that the mNG signals
32 corresponded to activated Sar1A and proceeded to further validate this methodology by
33 examining the activation of various Sar1A mutants.

1 The ΔN mutant, which fails to insert into the ER membrane, did not generate any
2 mNG signals despite expressing Sar1A at a level comparable to that of the wild-type
3 Sar1A, as indicated by FLAG staining (Fig. 1b)²⁵. This observation further supports the
4 notion that mNG signals reflect the activation status of Sar1A at the ER membrane.
5 Consistent with this finding, the T39N mutant, deficient in GTP binding, exhibited weak
6 signals throughout the ER, underscoring the necessity of Sar1A activation for robust
7 mNG signaling (Fig. 1b)²⁶. In contrast, the Sar1A H79G mutant, a GTPase-deficient
8 variant of Sar1A, generated strong mNG signals that colocalized with Sec16 (Fig. 1b)²⁷.

9 The localization of mNG signals in various mutants was consistent with previously
10 reported biochemical properties of Sar1¹⁹. Consequently, we conclude that the system
11 can detect the activation of small GTPases in living cells. We named this technology
12 Small GTPase ActIvitY ANalyzing (SAIYAN). Subsequently, we established cell lines
13 capable of detecting endogenous Sar1 activation. Endogenous Sar1A was tagged with
14 mNG₁₁ using CRISPR/Cas9-mediated knock-in tagging of HA-mNG₁₋₁₀ cells
15 (Supplementary Fig. 2). These cell lines were validated by sequencing the Sar1A genomic
16 locus and designated as Sar1A/SAIYAN (HeLa) cells. Consistent with the transient
17 expression, mNG signals were observed only upon doxycycline induction and were
18 exclusively localized at the ER exit sites (Fig. 1c, d). Using siRNAs suppressed Sar1
19 expression in Sar1A/SAIYAN (HeLa) cells, thereby diminishing mNG fluorescence (Fig.
20 1e). Quantification of the mNG signals is presented in Fig. 1f. Western blotting of cell
21 lysates confirmed the reduction in bands corresponding to Sar1A and FLAG (Fig. 1g),
22 further validating the production of Sar1A/SAIYAN (HeLa) cells. Moreover, no
23 significant difference in growth of Sar1A/SAIYAN (HeLa) cells was observed compared
24 to the parental HeLa cells, both with and without doxycycline induction, indicating that
25 the constructs were non-toxic to the cells (Supplementary Fig. 3a). Additionally, GM130
26 staining revealed a typical Golgi structure, further confirming that the constructs had no
27 effect on secretory pathways (Supplementary Fig. 3b).

28

29 **Sar1 activation is mediated by cTAGE5/Sec12 at ER exit sites in living cells**

30 The effects of Sec12 depletion were examined. Consistent with our expectations,
31 knockdown of Sec12 using siRNAs resulted in diminished mNG signals (Fig. 2a, b;
32 Supplementary Fig. 4a), verifying the role of Sec12 in mediating Sar1 activation at ER
33 exit sites²⁰. Our previous investigations demonstrated that the interaction between Sec12

1 and cTAGE5 is crucial for the appropriate localization of Sec12 to ER exit sites²⁸ and the
2 depletion of cTAGE5 disperses Sec12 throughout the ER²⁹. Therefore, the effect of
3 cTAGE5 depletion on Sar1 activity was examined. The depletion of cTAGE5 decreased
4 Sar1 activity at the ER exit sites (Fig. 2c, d), while the expression level of Sec12 remained
5 unchanged (Supplementary Fig. 4b). These findings indicate that the accurate positioning
6 of Sec12 at the ER exit sites is essential for the effective activation of Sar1 at these sites.
7

8 **ER exit site organization is crucial for proper Sar1 activation in living cells**

9 We investigated the effects of perturbing the organization of the ER exit sites on Sar1
10 activity. Our previous study demonstrated the interaction between TANGO1 and Sec16
11 and its significance in ER exit-site organization^{30, 31}. Consequently, we depleted
12 TANGO1 and Sec16, and examined their effects on Sar1 activity. The knockdown of
13 both TANGO1 and Sec16 resulted in reduced mNG signaling, indicating the essential
14 role of TANGO1 and Sec16 in facilitating Sar1 activation (Fig. 2 e–h; Supplementary
15 Fig. 4c, d).
16

17 **Sec23 acts as a stabilizer of activated Sar1 rather than an inactivator in living cells**

18 Our findings suggest that the absence of crucial ER exit-site components results in Sar1
19 inactivation. To assess whether the SAIYAN system could also detect an increase in Sar1
20 activity, Sec23A was depleted. Given that Sec23 promotes GTP hydrolysis of Sar1 *in*
21 *vitro*, its depletion should theoretically enhance Sar1 activity. However, Sar1 activity was
22 severely diminished in Sec23A-depleted cells (Fig. 3 a, b; Supplementary Fig. 5a).
23 Subsequently, we knocked down Sec31A, which is known to enhance Sec23 GAP
24 activity towards Sar1 by approximately ten-fold *in vitro*^{7, 32}. As anticipated, Sec31A
25 depletion increased Sar1 activity (Fig. 3c, d; Supplementary Fig. 5b). These results
26 suggest that the SAIYAN system can detect the augmentation of small GTPases.
27 Moreover, we confirmed in living mammalian cells that Sec23 serves as a stabilizer of
28 activated Sar1 rather than an inactivator, as previously suggested by structural and
29 biochemical analyses conducted *in vitro*³².
30

31 **CLSD mutants of Sec23A showed activity against Sar1, consistent with *in vitro* 32 studies**

1 Cranio-lenticulo-sutural dysplasia (CLSD; OMIM #607812) is a syndrome characterized
2 by facial dysmorphism, late-closing fontanels, congenital cataracts, and skeletal defects
3 caused by monoallelic or biallelic mutations in the Sec23A gene^{33, 34}. Two mutations,
4 F382L and M702V, have been extensively analyzed. While mutation in both alleles
5 causes the F382L mutation to induce CLSD, M702V causes the condition even when only
6 one allele is mutated. Discrepancies in the activities of both mutants towards Sar1A were
7 investigated *in vitro*. Although neither mutation significantly affected Sar1A incubated
8 as Sec23A/Sec24D in the absence of the Sec13/Sec31 complex, the presence of
9 Sec13/Sec31 resulted in a decrease in GAP activity towards Sar1A, particularly in the
10 presence of the F382L mutation^{35, 36}. Therefore, using the SAIYAN system, we examined
11 the impact of both mutations on living cells, that contained intrinsic Sec13/Sec31. Stable
12 expression of various mCherry-tagged Sec23A mutants was achieved in SAIYAN cells;
13 however, endogenous Sec23A expression was reduced, as shown in Supplementary Fig.
14 5c. Sar1 activity was measured in these cells. mNG signals were significantly stronger in
15 cells expressing the F382L mutation (Fig. 3e). This observation was further supported by
16 the quantitative results, which indicate a notable decrease in GAP activity towards Sar1A
17 in cells expressing the F382L mutation (Fig. 3f). Thus, SAIYAN cells allowed for the
18 effective observation of various effects of Sar1 in live cells.

19

20 Activated Sar1 prevails in the ERGIC region of collagen-secreting cells

21 Our results suggest that the SAIYAN system can detect Sar1 activity in HeLa cells. Next,
22 we investigated Sar1 activity in collagen-secreting cells. Sar1A/SAIYAN cell lines were
23 established from BJ-5ta cells, hTERT-immortalized fibroblasts of human foreskin
24 origin^{37, 38}. Genomic sequencing confirmed the production of SAIYAN cells, which were
25 designated as Sar1A/SAIYAN (BJ-5ta) cells. Cells treated with 2,2'-dipyridyl (DPD), a
26 prolyl hydroxylase inhibitor known to impede collagen folding, exhibited augmented
27 procollagen I accumulation within the ER, indicating collagen production and secretion
28 by the cell lines (Supplementary Fig. 6)^{39, 40}.

29 Subsequently, Sar1A/SAIYAN (BJ-5ta) cells were co-stained with Sec16. The cells were
30 visualized using Airyscan microscopy, showing a 1.4-fold improvement in lateral
31 resolution compared to traditional confocal imaging⁴¹. Sec16 exhibited punctate
32 localization within the cytoplasm, with a tendency to accumulate near the Golgi apparatus,
33 indicating the characteristic localization of ER exit sites, as observed in HeLa cells (Fig.

1 4a). Upon observing the mNG signal, the punctate localization showed a definite
2 colocalization with Sec16 (Fig. 4a). Notably, in addition to this pattern, the mNG signal
3 exhibited weak extension in a reticular pattern, with less colocalization with Sec16 (Fig.
4 4a). To further elucidate the nature of these membranous protrusions, we co-stained mNG
5 signals with various antibodies targeting proteins localized at the ER-Golgi interface.
6 This reticular pattern did not coincide with GM130 (Fig. 4m) or PDI (Fig. 4n), which are
7 markers for the Golgi and ER, respectively. However, these reticular membranes
8 containing mNG signals showed significant colocalization with the ERGIC-53 antibodies
9 (Fig. 4b). Conversely, Rab1A, an ERGIC marker, exhibited limited colocalization with
10 activated Sar1 (Fig. 4o). Additionally, Sec23 (Fig. 4c), Sec24B (Fig. 4d), and p125A (Fig.
11 4f), which are all inner COPII coat constituents, displayed substantial overlap with the
12 reticular membranes of activated Sar1. Additionally, the localization of Sec24D (Fig. 4e)
13 to the reticular signal in the ERGIC region was relatively weaker, and the degree of
14 colocalization with mNG was not as pronounced as that with other inner coat components
15 (Fig. 4p).

16 The spatial relationships between these proteins were further elucidated using triple
17 staining, as shown in Fig. 5. As demonstrated by dual staining, Sec16 overlapped with
18 mNG in dotted-like structures, but there is minimal overlap with the reticular patterns of
19 mNG (Fig. 5a). Additionally, as expected, ERGIC53 showed minimal colocalization with
20 Sec16 (Fig. 5a). In contrast, Sec23 not only overlapped with mNG but also colocalized
21 with ERGIC53, demonstrating that Sec23 is localized not only at the ER exit sites but
22 also across the ERGIC region (Fig. 5b). Furthermore, although ERGIC53 and Rab1a
23 partially overlapped, they exhibited distinct regions, suggesting their combined
24 involvement in shaping the ERGIC region (Fig. 5c). mNG signals exhibited considerable
25 overlap with ERGIC53 but minimal overlap with Rab1A, indicating mNG localization to
26 the ERGIC region where ERGIC53 predominates (Fig. 5c).

27 In contrast, ER exit-site proteins, including TANGO1 (Fig. 4g), Sec12 (Fig. 4h), and
28 TFG (Fig. 4i), only exhibited colocalization with dot-like structures similar to those of
29 Sec16. Notable, Sec13 (Fig. 4j) and Sec31A (Fig. 4k), which form the outer COPII coats,
30 exhibited less colocalization with mNG compared to the inner COPII coats, but more than
31 the resident proteins of the ER exit sites. These results indicate that activated Sar1
32 predominates in the ERGIC regions in conjunction with the inner COPII components

1 within collagen-secreting BJ-5ta cells. Conversely, proteins localized at the ER exit sites
2 remain confined within the contiguous domain of the ER.

3 Finally, we examined Sec23A localization in parental BJ-5ta cells. As shown in Fig.
4 5d, Sec23A extension was observed in the ERGIC region, confirming that the reticular
5 signals observed in SAIYAN cells were not a result of introducing the SAIYAN system
6 artificially. This observation further supports the extension of activated Sar1 to ERGIC
7 regions in collagen-secreting BJ-5ta cells.

8

9 **The regions of Sar1 activation depend on the cargo secreted by the cell**

10 The aforementioned observation was consistent with previous reports by Weigel et al.
11 and Shomron et al. regarding ER-Golgi protein transport mediated by an interconnected
12 tubular network rather than spherical vesicles, although their reports did not distinguish
13 between resident proteins at ER exit sites and COPII coats^{42, 43}. Furthermore, an
14 intriguing observation in their study was the involvement of COPI proteins in anterograde
15 transport. We investigated the spatial relationship between the COPI proteins and Sar1
16 activation in SAIYAN cells. Consistent with these findings, COPI proteins were localized
17 in close proximity to the activated Sar1 (Fig. 4l). Fig. 4p illustrates the colocalization
18 rates of activated Sar1 with various factors present at the ER-Golgi interface in
19 Sar1A/SAIYAN (BJ-5ta) cells. Inner COPII components, akin to ERGIC53, exhibit a
20 high degree of colocalization with activated Sar1, whereas outer COPII components and
21 COPI factors subsequently follow. The colocalization rate with resident proteins at ER
22 exit sites, such as Sec12, responsible for activating Sar1, was significantly lower
23 compared to these. A comparison of these results with the colocalization rates of mNG
24 signals with other components present at the ER-Golgi interface in Sar1A/SAIYAN
25 (HeLa) cells would be intriguing. In HeLa cells, the colocalization rate of activated Sar1
26 was moderately high with ER exit-site resident proteins, similar to inner and outer COPII,
27 whereas ERGIC and COPI exhibited comparatively lower colocalization
28 (Supplementary Fig. 7). These results suggest that the structure of the ER-Golgi interface
29 varies significantly depending on the nature of the secreting cells.

30 Additionally, to validate this, we treated Sar1A/SAIYAN (BJ-5ta) cells with DPD
31 and examined the change in the activation region of Sar1 upon the inhibition of collagen
32 secretion. Our results revealed that in cells treated with DPD, the previously observed
33 weak reticular signal, which was typical characteristic of BJ-5ta cells, disappeared, and

1 the mNG signal localized to the punctate structures, similar to that observed in HeLa cells
2 (Fig. 6a). In fact, the measurement of colocalization with Sec16 showed a significant
3 increase in DPD-treated cells compared to untreated cells (Fig. 6b). These findings
4 suggest that the ER-Golgi interface adopts different structures depending on the cargo
5 being secreted, thereby maintaining a shape customized for the specific cargo.
6 Furthermore, it became evident that activated Sar1 in collagen-secreting cells was
7 localized along with the inner COPII components from the ER exit site to the ERGIC
8 region.

9

10

1 DISCUSSION

2 In this study, we successfully visualized the activation of Sar1 in living cells for the first
3 time using Split Fluorescent Protein technology, designated as the SAIYAN system.
4 Previously, the measurement of Sar1 activation relied solely on *in vitro* biochemical
5 assays. However, SAIYAN technology accurately identified the activity of Sar1
6 modulators in living mammalian cells. Specifically, we directly measured the
7 requirement of Sec12 as a GEF and cTAGE5 as a recruiter for Sec12 in order to activate
8 Sar1 in living cells. Furthermore, we elucidated the roles of essential factors such as
9 TANGO1 and Sec16, which are components of ER exit sites, in facilitating appropriate
10 Sar1 activation. Additionally, we provided evidence in live mammalian cells that while
11 *in vitro* Sec23 exhibits GAP activity towards Sar1, it contributes to the stabilization of
12 activated Sar1 through pre-budding complex formation, consistent with previous analyses
13 of yeast and mammalian proteins^{7, 32}. Furthermore, we confirmed that Sec31 possesses
14 GAP-enhancing activity towards Sec23, which results in Sar1 inactivation. We also
15 obtained conclusions consistent with previous *in vitro* results regarding the activity of
16 well-analyzed CLSD-associated mutants of Sec23A, F382L, and M702V on Sar1A. The
17 M702V mutant has been reported to have more substantial effects on Sar1B than on
18 Sar1A³⁶. Further development and analysis with SAIYAN cells for Sar1B are anticipated
19 to enhance our understanding of CLSD within cells. We devised a novel system
20 employing SAIYAN technology, allowing real-time monitoring of the activation of small
21 GTPases in live cells that lacked firmly established effectors—a capability unattainable
22 with previous FRET probes.

23

24 We have previously demonstrated that Sec12 accumulates at the ER exit site in a
25 TANGO1- and cTAGE5-dependent manner and is necessary for efficient Sar1
26 activation^{28, 30}. cTAGE5 knockdown inhibits Sec12 accumulation and suppresses
27 collagen secretion. Furthermore, we demonstrated that the accumulation of Sec12 at ER
28 exit sites mediated by cTAGE5 can be complemented by the overexpression of wild-type
29 Sar1, indicating the importance of Sar1 activation at ER exit sites for collagen secretion²⁹.
30 However, contrary to our expectations, activated Sar1 was not confined solely to the ER
31 exit site but rather extended beyond the ER exit site and extended into the ERGIC region
32 in collagen-secreting cells, a phenomenon not observed in HeLa cells secreting minimal
33 collagen. Notably, upon the addition of DPD, a collagen folding inhibitor, we found that

1 activated Sar1 was specifically localized to the ER exit site, even in BJ-5ta cells. These
2 results strongly suggest that the specific localization of activated Sar1 to the ERGIC
3 region is crucial for collagen secretion. Moreover, the site of Sar1 activation and its
4 function may differ during the process of collagen secretion.

5

6 Based on the insights gained from the activation of Sar1 and collagen transport from the
7 ER, reports have indicated that the addition of Sar1 H79G to semi-intact cells results in
8 tubular structures that emanate from the ER⁴⁴. Similar tubular formation has been
9 observed when Sar1 H79G is introduced to artificial liposomes or incubated with non-
10 hydrolyzable GTP analogs such as GTP γ S and GMP-PNP^{7, 45, 46, 47}. These findings are
11 consistent with the hypothesis that upon Sar1 activation, the amphipathic N-terminal
12 region of Sar1 becomes embedded in the membrane, potentially inducing membrane
13 curvature^{22, 48}. Additionally, using cryo-electron microscopy, Zanetti et al. demonstrated
14 that non-hydrolysable Sar1 and COPII components incubated with giant unilamellar
15 vesicles induced the formation of tubes covered by Sec23/Sec24 and Sec13/Sec31⁴⁹.
16 Remarkably, their model predicted that the tubular structures covered with Sec23/Sec24
17 would recruit fewer Sec13/Sec31 compared to spherical vesicles. Additionally, an
18 enlarged COPII cage suggested a decrease in Sar1-GTP hydrolytic activity compared
19 with conventional COPII coats. We found that upon the secretion of collagen, activated
20 Sar1 extends from the ER exit site to the ERGIC region, where Sec23/Sec24 and p125
21 colocalize. This observation is consistent with the tubular structures identified by Zanetti
22 et al. upon the addition of GTP-locked Sar1 *in vitro*. Additionally, the co-localization of
23 Sec13/Sec31 with activated Sar1 was lower than that of inner coat factors, but higher than
24 that of ER exit site-resident proteins, thus supporting their proposed model. Mutations
25 in Sec24D (Fig. 4e) cause Osteogenesis Imperfecta (OI), suggesting that Sec24D is
26 involved in collagen secretion⁵⁰. Therefore, the observation that Sec24D is less
27 colocalized with activated Sar1 in ERGIC protrusions in collagen-secreting cells was
28 unexpected. However, evidence suggests that collagen accumulation is not significant in
29 Sec24D-deficient patient skin fibroblasts and that all Sec24 isoforms are involved in
30 collagen transport, indicating the need for further analysis^{50, 51}.

31

32 Furthermore, Malhotra et al. proposed the possibility of ERGIC membrane recruitment
33 to TANGO1 located at ER exit sites, suggesting the formation of large carriers necessary

1 for collagen secretion⁵². Subsequently, they proposed a model in which elongated tunnel-
2 like structures facilitate the secretion of collagen from the ER to the Golgi apparatus^{53, 54}.
3 Recent observations using live cells and electron microscopy have revealed reticular
4 structures at the ER-Golgi interface, indicating that protein transport may occur through
5 these reticular/tubular structures instead of vesicular transport alone. Nevertheless, these
6 studies primarily focused on the localization of inner and outer COPII proteins as
7 indicative of proteins at the ER-Golgi interface, which may not have clearly distinguished
8 between the resident proteins at the ER exit sites, COPII proteins, and proteins localized
9 at the ERGIC structures. Moreover, most of these analyses were confined to cells such as
10 HeLa, COS7, and CHO, which are known to secrete limited amounts of collagen^{42, 43}.
11 Our observations suggest that, at least in collagen-secreting cells, resident proteins at ER
12 exit sites and COPII proteins likely behave differently depending on the cell type. Thus,
13 our current analysis adds some modifications to their observations. A schematic
14 representation of the ER-Golgi interface is shown in Fig. 7. Factors such as TANGO1,
15 Sec16, Sec12, and TFG were localized specifically at the punctate structures commonly
16 referred to as ER exit sites in collagen-secreting cells, with no evident reticular structures
17 directed towards ERGIC (Fig. 7b). Conversely, inner coat proteins composed of
18 Sec23/Sec24 and p125A protruded towards the ERGIC direction, along with activated
19 Sar1, in addition to their localization at conventional ER exit sites (Fig. 7b). Activated
20 Sar1 was restricted to the ERGIC53-positive region of the ERGIC and was absent from
21 the Rab1 side of these cells (Fig. 7b). This observation correlates with a report indicating
22 that Surf4 is present in tubular ERGIC, which is Rab1-positive and ERGIC53-negative⁵⁵.
23 Furthermore, recent discoveries highlighting the interaction of p125 with VPS13B and its
24 role in collagen secretion via tubular ERGIC formation underscore its significance⁵⁶.
25 Moreover, our discovery that activated Sar1 in collagen-secreting cells demonstrates
26 stronger colocalization with β -COP compared to ER exit site proteins holds considerable
27 significance (Fig. 4p). This observation is consistent with prior evidence implicating
28 COPI in collagen secretion⁵⁷. In contrast, in HeLa cells, both resident and COPII
29 proteins were found to colocalize well with activated Sar1 at the ER exit sites, while
30 ERGIC and COPI exhibited less colocalization with activated Sar1 (Fig. 7a).

31

32 Our findings are consistent with both the vesicle-mediated and tunnel-mediated transport
33 models. It remains a challenge to determine whether all secretory proteins are exclusively

1 transported via reticular structures or if both vesicular transport and reticular structures
2 coexist⁵⁸. In this context, whether the differences in the structure of the ER-Golgi
3 interface can be attributed to the mode of secretion is a highly intriguing issue. The
4 mechanism by which activated Sar1 is stabilized and facilitates protrusions into the
5 ERGIC in collagen-secreting cells compared to minimal collagen-secreting cells remains
6 a subject for future investigation. Additionally, variations in the structure of the ER-Golgi
7 interface across different cell types suggest the flexibility of the ER-Golgi interface to
8 accommodate cargo types specific to each cell type. Indeed, in our experiments, treatment
9 of collagen-secreting cells with DPD resulted in their ER-Golgi interfaces resembling
10 those in HeLa cells. Recent studies indicating normal secretion in cells lacking Sar1 and
11 the role of mechanical strain in regulating secretion via Sar1 through Rac1 activity,
12 emphasize the importance of elucidating Sar1's role in secretion^{59, 60}. Thus, understanding
13 the role of Sar1 in vesicular secretion is critical for future research.

14

15 One limitation of the current approach is the inherent tendency of split fluorescent
16 proteins to self-associate to some extent¹⁸. While split fluorescent proteins have been
17 successfully utilized as factors forming membrane contact sites, improper levels of
18 expressed factors can lead to the formation of artificial contact sites⁶¹. During the process
19 of initial optimization of the system, when we lengthened the glycine linker attached to
20 Sar1, we observed mNG signals by SAIYAN, even in ΔN Sar1 mutants that were not
21 recruited to the membranes (data not shown). Therefore, the proposed system was
22 carefully validated. The ability to accurately measure both Sar1 inactivation and
23 activation through knockdown of each factor served as the foremost validation of the
24 functionality of the assay system. Therefore, careful validation, particularly to ensure the
25 absence of fluorescent signals in the absence of membrane recruitment, is crucial when
26 employing SAIYAN in other small GTPases for further analysis. Moreover, in future
27 iterations of SAIYAN, the use of more transiently interacting fluorescent probes will be
28 beneficial to measure the kinetics of GTPase turnover instead of monitoring long-term
29 changes using siRNA. Nevertheless, in this study, we successfully detected Sar1
30 activation in cells for the first time using split fluorescent proteins and gained intriguing
31 insights into the differential activation states of Sar1 across different cell types. By further
32 refining the SAIYAN technology, we anticipate gaining broader insights into the
33 intracellular activation of small GTPases.

1 **METHODS**

2 **Antibodies**

3 Polyclonal antibody against Sec13 were raised in rabbits by immunization with His-
4 Sec13 and affinity-purified by columns conjugated with GST-Sec13. Polyclonal antibody
5 against Sar1A were raised in rabbits by immunization with Sar1A and affinity-purified
6 by columns conjugated with Sar1A. Polyclonal antibody against TFG were raised in
7 rabbits by immunization with TFG (308-396aa.) and affinity-purified by columns
8 conjugated with corresponding region of TFG. Anti-Sec12 (rat), anti-Sec16-N (rabbit),
9 anti-Sec16-C (rabbit), anti-Sec23A (rat), anti-Sec31A(rabbit), anti-cTAGE5-CC1
10 (rabbit), anti-TANGO1-CC1 (rabbit) and anti-TANGO1-CT (rabbit) antibodies were
11 produced as described previously ^{28, 30, 62, 63, 64}. Sec24D antibody was gifted from
12 Schekman Lab. Other antibodies were as follows: GAPDH (mouse; Santacruz), FLAG
13 (mouse; Sigma-Aldrich or rat; Agilent), HA (rat; Roche), Sec31 (mouse; BD), Sec24B
14 (rabbit; Cell Signaling), p125A (rabbit;proteintech), β -COP (mouse;SIGMA), ERGIC53
15 (mouse; Santacruz), Rab1a (rabbit;Cell Signaling), GM130 (mouse; BD biosciences),
16 PDI (mouse;abcam).

17

18 **Constructs**

19 For transient expression of human Sar1A WT or mutant constructs, human Sar1A cDNA
20 fused with FLAG peptide, GS linker (GGGS), and 11th β strand of mNeonGreen2 to C
21 terminal was cloned into pCMV5 vectors that were gifts from D. Russell (University of
22 Texas Southwestern Medical Center, Dallas, TX) ⁶⁵. ΔN mutant lacks 25aa of N terminal,
23 which is corresponding to 23aa deletion of yeast constructs ²⁵.

24

25 **Cell culture and transfection**

26 HeLa cells were cultured in DMEM supplemented with 10% FBS. BJ-5ta cells were
27 cultured in high Glucose DMEM supplemented with Medium 199, 10% FBS, and
28 ascorbic acid phosphate. For transfecting siRNA, Lipofectamine RNAi max (Thermo
29 Fisher Scientific) was used. For single siRNA transfection, reverse transfection protocol
30 was used. In the case of double siRNA transfection, after 24h of the first transfection by
31 reverse transfection, forward transfection was conducted according to the manufacturer's
32 protocol. For plasmid transfection, Fugene 6 (Promega) or Fugene 4K (Promega) were
33 used. Doxycycline-inducible stable cell lines expressing TM-mNG₁₋₁₀ were made with

1 the lentivirus system described previously⁶⁶. TM-mNG₁₋₁₀ consists of 1–92 aa of
2 TANGO1S (transmembrane region of TANGO1S), HA peptide, and 1–213aa (1~10th β
3 strands) of mNeonGreen2. Proteins were induced by incubation with 1 μ g/ml doxycycline
4 for 24h. Stable cell lines expressing mCherry-Sec23A WT, F382L, and M702V were
5 made with lentivirus by replacing Cas9 in LentiCRISPRv2 with Sec23A cDNAs⁶⁷. 2,2'-
6 dipyridyl was purchased from TCI.

7

8 CRISPR-mediated knock-in

9 sgRNA was prepared essentially as previously described^{65, 68, 69}. The DNA template for
10 sgRNA was generated by PrimeSTAR GXL DNA Polymerase (TAKARA) by
11 overlapping PCR using a set of three primers: BS7R:5'- AAA AAA AGC ACC GAC GAC
12 TCG GTG C-3' and ML611R:5'- AAA AAA AGC ACC GAC TCG GTG CCA CTT
13 TTT CAA GTT GAT AAC GGA CTA GCC TTA TTT AAA CTT GCT ATG CTG TTT
14 CCA GCA TAG CTC TTA AAC-3' and Sar1a_sgRNA_F:5'- CCT CTA ATA CGA
15 CTC ACT ATA GGC AAT ATA CTG GGA GAG CCA GGT TTA AGA GCT ATG
16 CTG GAA-3'. In vitro transcription and sgRNA purification were performed by CUGA7
17 gRNA Synthesis Kit (NIPPON Gene). To construct the donor plasmid for homology-
18 directed repair, the Sar1 genome template was first amplified from HeLa genomic DNA
19 with following primers (CCGCTCTAGAACTAGTACCCAAATGAGCTCTGGC,
20 CGGTATCGATAAGCTTGCATCAGTATTAAATACACATG) and cloned into
21 pBSIISK(-) by In-Fusion HD cloning Kit (TAKARA). Next, BamHI sequence was
22 inserted into the middle of genomic Sar1 by using following primers
23 (TCCTTGGACGGTGAAAATAAAAGAGTTTACTTC,
24 TCCGTCAATATACTGGGAGAGCCAGCGG). Then, FLAG peptide, GS linker
25 (GGGS) and 214–229 aa of mNeonGreen2 corresponding to the 11th bundle of
26 mNeonGreen2 were inserted into BamHI locus, to express Sar1A as a fusion with these
27 sequences⁶⁵. The construct was then used as a donor template for ssDNA production by
28 Guide-it Long ssDNA production system v2 (TAKARA). Following primers
29 (GCATCAGTATTAAATACACATG, ACCCAAATGAGCTCTGGCCTCCATATC)
30 with or without 5' phosphorylation was used for amplifying dsDNA for Strandase
31 reaction to make ssDNA. For CRISPR/Cas9-mediated cell line generation of SAIYAN
32 cells, 1x10⁵ cells of HeLa cells or BJ-5ta cells expressing inducible TM-mNG2₁₋₁₀ were
33 transfected with 7.5 pmol of Cas9 (TAKARA), 7.5 pmol of sgRNA, and 0.64 pmol of

1 ssDNA by Nucleofector II (Lonza) or Neon Transfection System (Thermo Fisher
2 Scientific). Cas9 and sgRNA were incubated at room temperature for 20 min prior to
3 transfection. Electroporated cells were cultured in 24-well plates for 5-7 days and
4 transferred to 6-well plates prior to selection by fluorescence-activated single cell sorting
5 using FACS Melody (BD Biosciences).

6

7

8 **Cell viability assay**

9 Cell viability of cultured cells was quantified using the Cell Counting Kit 8 (DOJINDO
10 Labolatories).

11

12 **Western blotting**

13 The experiments were essentially performed as described previously²⁸. Cells extracted
14 with extraction buffer consisting of 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM
15 EDTA, 1% Triton X-100, and protease inhibitors were centrifuged at 20,000 g for 15 min
16 at 4°C. The blots were analyzed using ImageQuant LAS4000 or ImageQuant 800 (GE
17 Healthcare).

18

19 **siRNA oligos**

20 siRNA oligos used in this study is shown in Supplementary Table 1. The number in the
21 parentheses represents the starting base pair of the target sequence. For control siRNA,
22 Stealth RNAi siRNA Negative Control Med GC Duplex #2 (Thermofisher Scientific) was
23 used.

24

25

26 **Immunofluorescence microscopy**

27 Immunofluorescence microscopy analysis was performed as described previously²⁸. Cells
28 grown on coverslips were washed with PBS, fixed with methanol (6 min at -20°C), and
29 then washed with PBS and blocked in blocking solution (5% BSA in PBS with 0.1%
30 Triton X-100 for 15 min). After blocking, cells were stained with primary antibody (1 h
31 at room temperature) followed by incubation with Alexa Fluor-conjugated secondary
32 antibodies (Alexa Fluor 488, Alexa Fluor 568, and/or Alexa Fluor 647 for 1 h at room
33 temperature). Images were acquired with confocal laser scanning microscopy (Plan

1 Apochromat 63 \times /1.40 NA oil immersion objective lens; LSM 900; Carl Zeiss). The
2 acquired images were processed with Zen Blue software (Carl Zeiss). All imaging was
3 performed at room temperature. mNeonGreen intensity scanning was performed by Fiji-
4 ImageJ⁷⁰. Pearson's colocalization rate was analyzed by Zen Blue software (Carl Zeiss).
5 Data were analyzed by an un-paired two sample Student's t-test for two-group
6 comparisons, or a one-way analysis of variance (ANOVA) followed by Dunnett's test for
7 multiple comparisons using GraphPad Prism 8 software (GraphPad). All graphs were
8 created using GraphPad Prism 8 software (GraphPad).

9

10 **Acknowledgements**

11 This work was supported by Grants-in-Aid for Scientific Research (20K15740,
12 22H02760 to M.M. 23H05254 to Y.K. and 19K22612, 20H03203, 20H04897, 21K19470,
13 23H02430 to K.S.) from the Ministry of Education, Culture, Sports, Science and
14 Technology of Japan, by Akita University Support for Fostering Research Project to
15 M.M., Y.K., and K.S., by The Naito Foundation to K.S. and M.M., by Takeda Science
16 Foundation to K.S., by Toray Science Foundation (19-6005) to K.S., by The Sumitomo
17 Foundation to K.S., by Suzuken Memorial Foundation to K.S., by The Yasuda Medical
18 Foundation to K.S., by Foundation for Promotion of Cancer Research to K.S., by The
19 Asahi Glass Foundation to K.S., by Princess Takamatsu Cancer Research Foundation to
20 K.S., by Japan Foundation for Applied Enzymology to M.M., by Kato Memorial
21 Bioscience Foundation to M.M., by Astellas Foundation for Research on Metabolic
22 Disorders to M.M., by Inamori Foundation to M.M., by The Kao Foundation for Arts
23 and Sciences to M.M. and by Koyanagi Foundation to M.M.

24

25 **Author Contributions**

26 M.M. designed and performed research, analyzed data, and wrote the manuscript; M.A.
27 and Y.K. performed research; and K.S. designed and performed research, analyzed data,
28 and wrote the manuscript.

29

30 **Competing Interest**

31 The authors declare no competing interests.

32

33

1 **FIGURE LEGENDS**

2 **Fig. 1: Production of Sar1A/SAIYAN cells.** **a** Schematic representation of SAIYAN
3 technology. The membrane-spanning regions of TANGO1S and HA-tag fused to 10 of
4 the 11 bundles of mNG (mNG₁₋₁₀) were expressed in cells. In addition, Sar1A constructs
5 with a FLAG tag and a glycine linker fused to the 11th bundle of mNG (mNG₁₁) were
6 also expressed. Upon Sar1A activation, mNG₁₋₁₀ and mNG₁₁ combine to form the
7 complete mNG proteins, inducing mNG signals. **b** HA-mNG₁₋₁₀ cells transfected with the
8 indicated Sar1A constructs were fixed and stained with anti-Sec16-C and anti-FLAG
9 antibodies. Scale bars = 10 μ m. **c** Sar1A/SAIYAN (HeLa) cells, either treated or non-
10 treated with doxycycline, were fixed and stained with anti-HA and anti-PDI antibodies.
11 Boxed areas in the middle panels are shown at high magnification in the bottom panels.
12 Scale bars = 10 μ m. **d** Sar1A/SAIYAN (HeLa) cells, either treated or non-treated with
13 doxycycline, were fixed and stained with anti-HA and anti-FLAG antibodies. Boxed
14 areas in the middle panels are shown at high magnification in the bottom panels. Scale
15 bars = 10 μ m. **e** Sar1A/SAIYAN (HeLa) cells transfected with the indicated siRNAs were
16 fixed and stained with an anti-Sec16-C antibody. Scale bars = 10 μ m. **f** Quantification of
17 mNG intensity from **(e)**. (arbitrary units [A.U.]). Error bars represent the means \pm SEM.
18 **g** Sar1A/SAIYAN (HeLa) cells transfected with the indicated siRNAs were lysed, and
19 subjected to SDS-PAGE, followed by western blotting with anti-FLAG, anti-HA, anti-
20 Sar1A and anti-GAPDH antibodies.

21

22 **Fig. 2: ER exit site organization is required for the efficient activation of Sar1A.** **a,**
23 **c, e, g** Sar1A/SAIYAN (HeLa) cells transfected with the indicated siRNAs were fixed
24 and stained with anti-Sec16-C antibodies. Scale bars = 10 μ m. **b, d, f, h** Quantification
25 of mNG signals from **(a), (c), (e), (g)**, respectively (arbitrary units [A.U.]). Error bars
26 represent the means \pm SEM.

27

28 **Fig. 3: Sec23A and Sec31A depletion exert opposite effects on the activation of Sar1A**
29 **in living cells.** **a, c** Sar1A/SAIYAN (HeLa) cells transfected with the indicated siRNAs
30 were fixed and stained with anti-Sec16-C antibodies. Scale bars = 10 μ m. **b, d**
31 Quantification of mNG signals from **(a) and (c)**, respectively (arbitrary units [A.U.]).
32 Error bars represent the means \pm SEM. **e** Sar1A/SAIYAN (HeLa) cells stably expressing
33 mCherry-tagged Sec23A constructs as indicated were fixed and processed for

1 microscopic analysis. Scale bars = 10 μ m. **f** Quantification of mNG signals from **(e)**
2 (A.U.). Error bars represent the means \pm SEM.

3

4 **Fig. 4: Activated Sar1 prevails in the ERGIC region of Sar1A/SAIYAN (BJ-5ta) cells.**
5 Sar1A/SAIYAN (BJ-5ta) cells were fixed and stained with anti-Sec16-C **(a)**, anti-
6 ERGIC53 **(b)**, anti-Sec23 **(c)**, anti-Sec24B **(d)**, anti-Sec24D **(e)**, anti-p125A **(f)**, anti-
7 TANGO1-CT **(g)**, anti-Sec12 **(h)**, anti-TFG **(i)**, anti-Sec13 **(j)**, anti-Sec31A (mouse) **(k)**,
8 anti- β -COP **(l)**, anti-GM130 **(m)**, anti-PDI **(n)**, anti-Rab1A **(o)** antibodies. Images were
9 captured using Airyscan2. Scale bars = 10 μ m. **a-l** (right; upper) Magnification of the
10 indicated regions is on the left. (right; bottom) Magnification of the indicated regions on
11 the upper. **p** Pearson's correlation coefficient was used to quantify the degree of
12 colocalization. n=5. cyan; outer COPII coats, blue; inner COPII coats, purple; ER exit
13 site resident proteins, red; ERGIC proteins, orange; COPI protein, magenta; ER and Golgi
14 proteins. Error bars represent the mean 95% CI.

15

16 **Fig. 5: Triple staining of Sar1A/SAIYAN(BJ-5ta) and parental BJ-5ta reveals the**
17 **organization of the ER-Golgi interface of collagen-secreting cells.**

18 **a-c** Sar1A/SAIYAN (BJ-5ta) cells were fixed and stained with anti-Sec16-C and anti-
19 ERGIC53 **(a)**, anti-Sec23 and anti-ERGIC53 **(b)**, and anti-Rab1A and anti-ERGIC53 **(c)**
20 antibodies. Images were captured using the Airyscan2. Scale bars = 10 μ m. **d** BJ-5ta cells
21 were fixed and stained with anti-Sec16-C, anti-Sec23, and anti-ERGIC53 antibodies.
22 Images were captured using the Airyscan2. Scale bars = 10 μ m. **a-d** (right; upper)
23 Magnification of the indicated regions is on the left. (right; bottom). Double staining of
24 the magnified region on the upper.

25

26 **Fig. 6: Reticular pattern of activated Sar1 signals diminished with DPD treatment**
27 **in Sar1A/SAIYAN (BJ-5ta) cells.** **a** Sar1A/SAIYAN (BJ-5ta) cells were treated with
28 DMSO or 0.5 mM DPD and incubated for 16 h. Cells were fixed and stained with anti-
29 Sec16-C antibodies. Images were captured using the Airyscan2. Scale bars = 10 μ m. **b**
30 Pearson's correlation coefficient was quantified to assess the degree of colocalization.
31 n=5. Error bars represent the mean 95% CI.

32

33

1 **Fig. 7: Schematic representation of ER-Golgi interfaces observed with SAIYAN**
2 **system. a** In HeLa cells, ER exit site resident proteins exhibit strong colocalization with
3 inner and outer COPII coat proteins at the ER exit sites. In contrast, ERGIC is located
4 away from the ER exit sites. **b** In collagen-secreting BJ-5ta cells, although ER exit site
5 resident proteins are confined to the ER exit sites, inner COPII coats extend to the ERGIC
6 regions labeled with ERGIC-53 but not Rab1. Outer coat proteins partially colocalize
7 with ER exit sites.

8
9

1 **REFERENCES**

2 1. Cherfils J. Small GTPase signaling hubs at the surface of cellular membranes in
3 physiology and disease. *FEBS Lett* **597**, 717-720 (2023).

4

5 2. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. *Physiol Rev* **81**,
6 153-208 (2001).

7

8 3. Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs.
9 *Physiol Rev* **93**, 269-309 (2013).

10

11 4. Saito K, Maeda M, Katada T. Regulation of the Sar1 GTPase Cycle Is
12 Necessary for Large Cargo Secretion from the Endoplasmic Reticulum. *Front
13 Cell Dev Biol* **5**, 75 (2017).

14

15 5. Northup JK, Smigel MD, Gilman AG. The guanine nucleotide activating site of
16 the regulatory component of adenylate cyclase. Identification by ligand binding.
17 *J Biol Chem* **257**, 11416-11423 (1982).

18

19 6. Goody PR. Intrinsic protein fluorescence assays for GEF, GAP and post-
20 translational modifications of small GTPases. *Anal Biochem* **515**, 22-25 (2016).

21

22 7. Antonny B, Madden D, Hamamoto S, Orci L, Schekman R. Dynamics of the
23 COPII coat with GTP and stable analogues. *Nat Cell Biol* **3**, 531-537 (2001).

24

25 8. Neal SE, Eccleston JF, Webb MR. Hydrolysis of GTP by p21NRAS, the NRAS
26 protooncogene product, is accompanied by a conformational change in the wild-
27 type protein: use of a single fluorescent probe at the catalytic site. *Proc Natl
28 Acad Sci U S A* **87**, 3562-3565 (1990).

29

30 9. Satoh T, Endo M, Nakamura S, Kaziro Y. Analysis of guanine nucleotide bound
31 to ras protein in PC12 cells. *FEBS Lett* **236**, 185-189 (1988).

32

1 10. Gibbs JB, Schaber MD, Marshall MS, Scolnick EM, Sigal IS. Identification of
2 guanine nucleotides bound to ras-encoded proteins in growing yeast cells. *J Biol
3 Chem* **262**, 10426-10429 (1987).

4

5 11. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an
6 activation-specific probe for Ras. *Oncogene* **14**, 623-625 (1997).

7

8 12. Taylor SJ, Shalloway D. Cell cycle-dependent activation of Ras. *Curr Biol* **6**,
9 1621-1627 (1996).

10

11 13. Aoki K, Matsuda M. Visualization of small GTPase activity with fluorescence
12 resonance energy transfer-based biosensors. *Nat Protoc* **4**, 1623-1631 (2009).

13

14 14. Mochizuki N, *et al.* Spatio-temporal images of growth-factor-induced activation
15 of Ras and Rap1. *Nature* **411**, 1065-1068 (2001).

16

17 15. Kakimoto Y, Tashiro S, Kojima R, Morozumi Y, Endo T, Tamura Y.
18 Visualizing multiple inter-organelle contact sites using the organelle-targeted
19 split-GFP system. *Sci Rep* **8**, 6175 (2018).

20

21 16. Magliery TJ, *et al.* Detecting protein-protein interactions with a green
22 fluorescent protein fragment reassembly trap: scope and mechanism. *J Am Chem
23 Soc* **127**, 146-157 (2005).

24

25 17. Cabantous S, Terwilliger TC, Waldo GS. Protein tagging and detection with
26 engineered self-assembling fragments of green fluorescent protein. *Nat
27 Biotechnol* **23**, 102-107 (2005).

28

29 18. Romei MG, Boxer SG. Split Green Fluorescent Proteins: Scope, Limitations,
30 and Outlook. *Annu Rev Biophys* **48**, 19-44 (2019).

31

32 19. Van der Verren SE, Zanetti G. The small GTPase Sar1, control centre of COPII
33 trafficking. *FEBS Lett* **597**, 865-882 (2023).

1

2 20. Barlowe C, Schekman R. SEC12 encodes a guanine-nucleotide-exchange factor
3 essential for transport vesicle budding from the ER. *Nature* **365**, 347-349
4 (1993).

5

6 21. Huang M, *et al.* Crystal structure of Sar1-GDP at 1.7 Å resolution and the role
7 of the NH₂ terminus in ER export. *J Cell Biol* **155**, 937-948 (2001).

8

9 22. Bi X, Corpina RA, Goldberg J. Structure of the Sec23/24-Sar1 pre-budding
10 complex of the COPII vesicle coat. *Nature* **419**, 271-277 (2002).

11

12 23. Yoshihisa T, Barlowe C, Schekman R. Requirement for a GTPase-activating
13 protein in vesicle budding from the endoplasmic reticulum. *Science* **259**, 1466-
14 1468 (1993).

15

16 24. Watson P, Townley AK, Koka P, Palmer KJ, Stephens DJ. Sec16 defines
17 endoplasmic reticulum exit sites and is required for secretory cargo export in
18 mammalian cells. *Traffic* **7**, 1678-1687 (2006).

19

20 25. Lee MC, Orci L, Hamamoto S, Futai E, Ravazzola M, Schekman R. Sar1p N-
21 terminal helix initiates membrane curvature and completes the fission of a
22 COPII vesicle. *Cell* **122**, 605-617 (2005).

23

24 26. Kuge O, *et al.* Sar1 promotes vesicle budding from the endoplasmic reticulum
25 but not Golgi compartments. *J Cell Biol* **125**, 51-65 (1994).

26

27 27. Aridor M, Bannykh SI, Rowe T, Balch WE. Sequential coupling between COPII
28 and COPI vesicle coats in endoplasmic reticulum to Golgi transport. *J Cell Biol*
29 **131**, 875-893 (1995).

30

31 28. Saito K, Yamashiro K, Shimazu N, Tanabe T, Kontani K, Katada T.
32 Concentration of Sec12 at ER exit sites via interaction with cTAGE5 is required
33 for collagen export. *J Cell Biol* **206**, 751-762 (2014).

1

2 29. Tanabe T, Maeda M, Saito K, Katada T. Dual function of cTAGE5 in collagen

3 export from the endoplasmic reticulum. *Mol Biol Cell* **27**, 2008-2013 (2016).

4

5 30. Maeda M, Katada T, Saito K. TANGO1 recruits Sec16 to coordinately organize

6 ER exit sites for efficient secretion. *J Cell Biol* **216**, 1731-1743 (2017).

7

8 31. Saito K, Maeda M. Not just a cargo receptor for large cargoes; an emerging role

9 of TANGO1 as an organizer of ER exit sites. *J Biochem* **166**, 115-119 (2019).

10

11 32. Bi X, Mancias JD, Goldberg J. Insights into COPII coat nucleation from the

12 structure of Sec23.Sar1 complexed with the active fragment of Sec31. *Dev Cell*

13 **13**, 635-645 (2007).

14

15 33. Boyadjiev SA, *et al.* Cranio-lenticulo-sutural dysplasia is caused by a SEC23A

16 mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking. *Nat*

17 *Genet* **38**, 1192-1197 (2006).

18

19 34. Boyadjiev SA, *et al.* Cranio-lenticulo-sutural dysplasia associated with defects

20 in collagen secretion. *Clin Genet* **80**, 169-176 (2011).

21

22 35. Fromme JC, *et al.* The genetic basis of a craniofacial disease provides insight

23 into COPII coat assembly. *Dev Cell* **13**, 623-634 (2007).

24

25 36. Kim SD, *et al.* The [corrected] SEC23-SEC31 [corrected] interface plays critical

26 role for export of procollagen from the endoplasmic reticulum. *J Biol Chem* **287**,

27 10134-10144 (2012).

28

29 37. Bodnar AG, *et al.* Extension of life-span by introduction of telomerase into

30 normal human cells. *Science* **279**, 349-352 (1998).

31

1 38. Jiang XR, *et al.* Telomerase expression in human somatic cells does not induce
2 changes associated with a transformed phenotype. *Nat Genet* **21**, 111-114
3 (1999).

4

5 39. Bonfanti L, *et al.* Procollagen traverses the Golgi stack without leaving the
6 lumen of cisternae: evidence for cisternal maturation. *Cell* **95**, 993-1003 (1998).

7

8 40. Mironov AA, *et al.* ER-to-Golgi carriers arise through direct en bloc protrusion
9 and multistage maturation of specialized ER exit domains. *Dev Cell* **5**, 583-594
10 (2003).

11

12 41. Huff J. The Airyscan detector from ZEISS: confocal imaging with improved
13 signal-to-noise ratio and super-resolution. *Nature Methods*, - i (2015).

14

15 42. Weigel AV, *et al.* ER-to-Golgi protein delivery through an interwoven, tubular
16 network extending from ER. *Cell* **184**, 2412-2429.e2416 (2021).

17

18 43. Shomron O, *et al.* COPII collar defines the boundary between ER and ER exit
19 site and does not coat cargo containers. *J Cell Biol* **220**, (2021).

20

21 44. Aridor M, *et al.* The Sar1 GTPase coordinates biosynthetic cargo selection with
22 endoplasmic reticulum export site assembly. *J Cell Biol* **152**, 213-229 (2001).

23

24 45. Bielli A, Haney CJ, Gabreski G, Watkins SC, Bannykh SI, Aridor M.
25 Regulation of Sar1 NH₂ terminus by GTP binding and hydrolysis promotes
26 membrane deformation to control COPII vesicle fission. *J Cell Biol* **171**, 919-
27 924 (2005).

28

29 46. Long KR, *et al.* Sar1 assembly regulates membrane constriction and ER export.
30 *J Cell Biol* **190**, 115-128 (2010).

31

32 47. Bacia K, *et al.* Multibudded tubules formed by COPII on artificial liposomes.
33 *Sci Rep* **1**, 17 (2011).

1

2 48. Paul S, Audhya A, Cui Q. Molecular mechanism of GTP binding- and

3 dimerization-induced enhancement of Sar1-mediated membrane remodeling.

4 *Proc Natl Acad Sci U S A* **120**, e2212513120 (2023).

5

6 49. Zanetti G, *et al.* The structure of the COPII transport-vesicle coat assembled on

7 membranes. *Elife* **2**, e00951 (2013).

8

9 50. Garbes L, *et al.* Mutations in SEC24D, Encoding a Component of the COPII

10 Machinery, Cause a Syndromic Form of Osteogenesis Imperfecta. *Am J Hum*

11 *Genet*, (2015).

12

13 51. Lu CL, *et al.* Collagen has a unique SEC24 preference for efficient export from

14 the endoplasmic reticulum. *Traffic* **23**, 81-93 (2022).

15

16 52. Santos AJ, Raote I, Scarpa M, Brouwers N, Malhotra V. TANGO1 recruits

17 ERGIC membranes to the endoplasmic reticulum for procollagen export. *Elife* **4**,

18 e10982 (2015).

19

20 53. Raote I, Malhotra V. Protein transport by vesicles and tunnels. *J Cell Biol* **218**,

21 737-739 (2019).

22

23 54. Bunel L, Pincet L, Malhotra V, Raote I, Pincet F. A model for collagen secretion

24 by intercompartmental continuities. *Proc Natl Acad Sci U S A* **121**,

25 e2310404120 (2024).

26

27 55. Yan R, Chen K, Wang B, Xu K. SURF4-induced tubular ERGIC selectively

28 expedites ER-to-Golgi transport. *Dev Cell* **57**, 512-525.e518 (2022).

29

30 56. Du A, Fan X, Song C, Xiong J, Ji WK. Sec23IP recruits the Cohen syndrome

31 factor VPS13B/COH1 to ER exit site-Golgi interface for tubular ERGIC

32 formation. *bioRxiv*, 2024.2002.2028.582656 (2024).

33

1 57. Raote I, *et al.* TANGO1 builds a machine for collagen export by recruiting and
2 spatially organizing COPII, tethers and membranes. *Elife* **7**, (2018).

3

4 58. Phuyal S, Farhan H. Want to leave the ER? We offer vesicles, tubules, and
5 tunnels. *J Cell Biol* **220**, (2021).

6

7 59. Kasberg W, *et al.* The Sar1 GTPase is dispensable for COPII-dependent cargo
8 export from the ER. *Cell Rep* **42**, 112635 (2023).

9

10 60. Phuyal S, *et al.* Mechanical strain stimulates COPII-dependent secretory
11 trafficking via Rac1. *EMBO J* **41**, e110596 (2022).

12

13 61. Tashiro S, Kakimoto Y, Shinmyo M, Fujimoto S, Tamura Y. Improved Split-
14 GFP Systems for Visualizing Organelle Contact Sites in Yeast and Human
15 Cells. *Front Cell Dev Biol* **8**, 571388 (2020).

16

17 62. Saito K, *et al.* cTAGE5 mediates collagen secretion through interaction with
18 TANGO1 at endoplasmic reticulum exit sites. *Mol Biol Cell* **22**, 2301-2308
19 (2011).

20

21 63. Maeda M, Saito K, Katada T. Distinct isoform-specific complexes of TANGO1
22 cooperatively facilitate collagen secretion from the endoplasmic reticulum. *Mol
23 Biol Cell* **27**, 2688-2696 (2016).

24

25 64. Maeda M, Komatsu Y, Saito K. Mitotic ER Exit Site Disassembly and
26 Reassembly Are Regulated by the Phosphorylation Status of TANGO1. *Dev
27 Cell*, (2020).

28

29 65. Feng S, Sekine S, Pessino V, Li H, Leonetti MD, Huang B. Improved split
30 fluorescent proteins for endogenous protein labeling. *Nat Commun* **8**, 370
31 (2017).

32

1 66. Shin KJ, *et al.* A single lentiviral vector platform for microRNA-based
2 conditional RNA interference and coordinated transgene expression. *Proc Natl
3 Acad Sci U S A* **103**, 13759-13764 (2006).

4

5 67. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries
6 for CRISPR screening. *Nat Methods* **11**, 783-784 (2014).

7

8 68. Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human
9 genome engineering by controlled timing of CRISPR/Cas9 delivery. *Elife* **3**,
10 e04766 (2014).

11

12 69. Leonetti MD, Sekine S, Kamiyama D, Weissman JS, Huang B. A scalable
13 strategy for high-throughput GFP tagging of endogenous human proteins. *Proc
14 Natl Acad Sci U S A* **113**, E3501-3508 (2016).


15

16 70. Schindelin J, *et al.* Fiji: an open-source platform for biological-image analysis.
17 *Nat Methods* **9**, 676-682 (2012).


18

19


a




b




c




d



e



f



g




Fig. 1




Fig. 2




Fig. 3




Fig. 4





a**b****c****d**

Fig. 5




Fig. 6




Fig. 7